弥漫大B细胞淋巴瘤的基因分型进展  

Progress on Genotyping of Diffuse Large B-Cell Lymphoma

作　　者：李小凡 郭新红[1] 

机构地区：[1]新疆医科大学第一附属医院血液科,新疆 乌鲁木齐

出　　处：《临床医学进展》2023年第12期19238-19243,共6页Advances in Clinical Medicine

摘　　要：弥漫大B细胞淋巴瘤(Diffuse Large B-cell Lymphoma, DLBCL)是血液系统恶性肿瘤,具有高度异质性,R-CHOP方案作为一线治疗方案,已不能满足临床需求,随着基因检测技术的飞快进展,探讨DLBCL在分子遗传学方面的异常成为可能,基于基因异常变化的基因亚型分型被人们熟知,也为个体化治疗及靶向药物研究提供更多参考依据。本文就目前最新的DLBCL基因分型进行论述。Diffuse large B-cell lymphoma (DLBCL) is a malignant tumor of hematological system, which is highly heterogeneous. R-CHOP regimen can no longer be clinically needed as a first-line treatment regimen. With the rapid development of gene detection technology, it is possible to explore the mo-lecular genetic abnormalities of DLBCL. Genotyping based on abnormal gene changes is well known and provides more reference for individualized therapy and targeted drug research. In this paper, the latest genotyping of DLBCL is discussed.

关 键 词：弥漫大B细胞淋巴瘤 免疫表型 分子生物学 MICM分型 

分 类 号：R73[医药卫生—肿瘤]